

# Validation data for CL075

<https://www.invivogen.com/cl075>

For research use only

Version 22A06-MM

CL075 (3M002) is a thiazoloquinolone derivative that induces differential TLR7 and/or TLR8 responses in human and murine immune cells. CL075 was originally described as a human TLR8 (hTLR8) agonist because it triggers a potent NF- $\kappa$ B activation in hTLR8 reporter cells when compared to hTLR7 reporter cells.

When tested with InvivoGen's reporter cells, CL075 generated a dose-dependent induction of the NF- $\kappa$ B signaling pathway in HEK-Blue™ hTLR7 cells, HEK-Blue™ mTLR7 cells, and HEK-Blue™ hTLR8 cells (Figure 1). CL075 does not activate InvivoGen's HEK-Blue™ mTLR8 reporter cells (Figure 1). Of note, CL075 is more potent for hTLR8 and mTLR7 activation than for hTLR7 (Figure 1).

## Evaluation of CL075 in HEK-Blue™ TLR7 and HEK-Blue™ TLR8 cells




Figure 1. CL075 induces a dose-dependent response in HEK-Blue™ TLR7 and HEK-Blue™ TLR8 cells. HEK-Blue™ hTLR7, HEK-Blue™ mTLR7, HEK-Blue™ hTLR8, and HEK-Blue™ mTLR8 cells were stimulated with increasing concentrations of CL075. After overnight incubation, CL075-induced TLR7/TLR8 signaling was assessed by measuring the levels of SEAP using QUANTI-Blue™ Solution and by reading the optical density (OD) at 630 nm.

### TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873  
InvivoGen USA (International): +1 (858) 457-5873  
InvivoGen Europe: +33 (0) 5-62-71-69-39  
InvivoGen Asia: +852 3622-3480  
E-mail: [info@invivogen.com](mailto:info@invivogen.com)